Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports.
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...
Investment analysts at Stifel Nicolaus started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat reports.
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation ...
On Monday, Stifel analysts began coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), assigning the biopharmaceutical company a Buy rating and setting a price target of $36.00. According to ...
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today ...
On Monday, Stifel analysts began coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), assigning the biopharmaceutical company a Buy rating and setting a price target of $36.00. According to InvestingPro ...
WAYNE, Pa. and ROCKVILLE, Md. - Avalo Therapeutics, Inc. (NASDAQ: AVTX), a biotech firm focusing on immune dysregulation treatments with a market capitalization of $91 million, today announced the ...
WAYNE, Pa. and ROCKVILLE, Md. - Avalo Therapeutics, Inc. (NASDAQ: AVTX), a biotech firm focusing on immune dysregulation treatments with a market capitalization of $91 million, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback